CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)
Status:
Completed
Trial end date:
2016-03-14
Target enrollment:
Participant gender:
Summary
The study consisted of 2 sequential parts. Part A assessed the safety and tolerability of
CAVATAK administered via intravesical instillation in patients with non-muscle invasive
bladder cancer scheduled to undergo TUR. Part B assessed the safety and tolerability of
CAVATAK administered in sequential combination with low dose Mitomycin C in the same patient
population.